Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	10 Mar 2025	Sun Pharmaceutical	BOB Capital Markets Ltd.	1677.60	2086.00	1611.50 (4.10%)	24.34	Buy	pdf post cache	Broker Report Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio BOB Capital Markets Ltd. SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn pdf Copy Link Share on Share on Share on Share on Alert
	01 Mar 2025	UltraTech Cement	BOB Capital Markets Ltd.	11210.00	13137.00	10128.45 (10.68%)	17.19	Buy	pdf post cache	Broker Report Ultratech Cement (BUY): Diversification Play; Sharp focus on Cement Stays, Retain BUY BOB Capital Markets Ltd. UTCEM allocates Rs18bn (~2% of capital allocation) in the building material value chain by investing in wire and cable business pdf Copy Link Share on Share on Share on Share on Alert
	24 Feb 2025	Federal Bank	BOB Capital Markets Ltd. Target	202.06	236.00	181.24 (11.49%)	16.80	Buy	pdf post cache	Broker Report Federal Bank (BUY): Unfolding strategy, implementation remains the key BOB Capital Markets Ltd. FB plans to grow advances 1.5x nominal GDP growth in the next three years pdf Copy Link Share on Share on Share on Share on Alert
	17 Feb 2025	Hindware Home Innovation	BOB Capital Markets Ltd. Target	270.60	250.00	194.90 (38.84%)	Target met	Buy	pdf post cache	Broker Report Hindware Home Innovation (BUY): Another disappointing quarter on muted demand BOB Capital Markets Ltd. Dismal Q3 on weak performance across segments due to muted demand environment pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2025	Ashok Leyland	BOB Capital Markets Ltd. Target	236.03	274.00	217.07 (8.73%)	16.09	Buy	pdf post cache	Broker Report Ashok Leyland (BUY): Cost and realisation a positive surprise, retain BUY BOB Capital Markets Ltd. Q3FY25 revenue grew 2%/8% YoY/QoQ to Rs 94.76bn, helped by realisation gains of 4%/6% YoY/QoQ while volume was listless pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2025	Lupin	BOB Capital Markets Ltd. Target	1957.70	2626.00	2055.25 (-4.75%)	34.14	Buy	pdf post cache	Broker Report Lupin (BUY): High-margin US region to have growth visibility till FY27 BOB Capital Markets Ltd. US sales cc quarterly run rate at its highest-ever level of US$ 235mn, expect to inch up to US$ 250mn in FY26E and US$ 280mn in FY27E pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2025	Birlasoft	BOB Capital Markets Ltd.	400.50	466.00	502.65 (-20.32%)	Target met	Sell	pdf post cache	Broker Report Birlasoft (SELL): Misses expectations: Company struggles within Tier 2 set BOB Capital Markets Ltd. 3QFY25 performance impacted by higher-than-expected furloughs and decline in ERP Biz. Revenue declined by 1.1% QoQ in CC terms pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2025	Alembic Pharma	BOB Capital Markets Ltd. Target	1018.05	1032.00	845.15 (20.46%)	Target met	Buy	pdf post cache	Broker Report Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base BOB Capital Markets Ltd. US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each pdf Copy Link Share on Share on Share on Share on Alert
	11 Feb 2025	Century Plyboards	BOB Capital Markets Ltd. Target	777.90	800.00	803.55 (-3.19%)	Target met	Hold	pdf post cache	Broker Report Century Plyboards (HOLD): Strong performance in a challenging environment BOB Capital Markets Ltd. CPBI beats our estimate on strong plywood sales volume and sharp sequential improvement in MDF margin pdf Copy Link Share on Share on Share on Share on Alert
	11 Feb 2025	VST Tillers Tractors	BOB Capital Markets Ltd. Target	3842.30	3267.00	3835.75 (0.17%)	Target met	Sell	pdf post cache	Broker Report VST Tillers Tractors (SELL): Listless show, limited near-term respite; maintain SELL BOB Capital Markets Ltd. Q3 revenue grew 29% YoY (-23% MoM) to ~Rs 2.2bn, driven by volume gain of ~34%, dragged by 4% lower realisations of Rs 0.27mn (YoY) pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Ultratech Cement (BUY): Diversification Play; Sharp focus on Cement Stays, Retain BUY

Federal Bank (BUY): Unfolding strategy, implementation remains the key

Hindware Home Innovation (BUY): Another disappointing quarter on muted demand

Ashok Leyland (BUY): Cost and realisation a positive surprise, retain BUY

Lupin (BUY): High-margin US region to have growth visibility till FY27

Birlasoft (SELL): Misses expectations: Company struggles within Tier 2 set

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Century Plyboards (HOLD): Strong performance in a challenging environment

VST Tillers Tractors (SELL): Listless show, limited near-term respite; maintain SELL

Advisor Screeners